Candel Therapeutics (CADL) shares climbed by more than 120% in premarket trading after the biopharmaceutical company said a phase 3 trial of CAN-2409 to treat localized prostate cancer met its primary endpoint.
The primary endpoint was to demonstrate a statistically significant improvement in disease-free survival compared to the control arm.
The company said that based on the study's results it plans to begin discussions with the US Food and Drug Administration about a regulatory pathway for CAN-2409 to treat localized prostate cancer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。